oral JAK 1 and JAK 2 inhibitor

Novartis Received The European Commission Approval for Jakavi
Dec 7, 2012
Novartis, Incyte's strategic collaborator, has received the European Commission approval for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor to treat patients with myelofibrosis. The oral JAK 1 and JAK 2 inhibitor ...

Tags: Jakavi, oral JAK 1 and JAK 2 inhibitor, Novartis